Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths

N. Cutler, G. R. Mushet, R. Davis, B. Clements, L. Whitcher, John L. Benedum, Milan L. Brandon, Neal Cutler, David Ginsberg, Claude B. Goswick, Andrew D. Grubbs, Frank W. Kilpatrick, John Claude Krusz, Hubert A. Leonard, Brain E. Mondell, James D. Mumper, George R. Mushet, Elson So

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

This randomized, double–blind, parallel–group, placebo–controlled study evaluated the efficacy and tolerability of oral sumatriptan )Imitrex tablets( in 259 migraineurs. In the clinic, patients received oral sumatriptan 25 mg, 50 mg, or 100 mg, or placebo for the treatment of a migraine attack. The results indicate that by 2 hours post– dose, 50 to 56% of patients treated with any of the three doses, compared with 26% of patients treated with placebo, achieved relief of headache )p <; 0.05 for each sumatriptan group vs placebo(. By 4 hours postdose, 68 to 71% of suma– triptan–treated patients, compared with 38% of placebo–treated patients, achieved relief of headache )p < 0.05 for each sumatriptan group vs placebo(. Oral sumatriptan was similarly effective at relieving nausea and photophobia and at reducing clinical disability. The pattern and incidence of adverse events did not differ between treatment groups. All doses–25 mg, 50 mg, and 100 mg–of sumatriptan were effective and generally well tolerated. Dosing should be indi– vidualized according to the needs of the patient. NEUROLOGY 1995;45)suppl 7(:S5–S9

Original languageEnglish (US)
Pages (from-to)S5-S9
JournalNeurology
Volume45
Issue number8
StatePublished - 1995
Externally publishedYes

Fingerprint

Sumatriptan
Migraine Disorders
Placebos
Headache
Therapeutics
Photophobia
Nausea
Tablets
Evaluation
Placebo
Incidence

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Cutler, N., Mushet, G. R., Davis, R., Clements, B., Whitcher, L., Benedum, J. L., ... So, E. (1995). Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Neurology, 45(8), S5-S9.

Oral sumatriptan for the acute treatment of migraine : Evaluation of three dosage strengths. / Cutler, N.; Mushet, G. R.; Davis, R.; Clements, B.; Whitcher, L.; Benedum, John L.; Brandon, Milan L.; Cutler, Neal; Ginsberg, David; Goswick, Claude B.; Grubbs, Andrew D.; Kilpatrick, Frank W.; Krusz, John Claude; Leonard, Hubert A.; Mondell, Brain E.; Mumper, James D.; Mushet, George R.; So, Elson.

In: Neurology, Vol. 45, No. 8, 1995, p. S5-S9.

Research output: Contribution to journalArticle

Cutler, N, Mushet, GR, Davis, R, Clements, B, Whitcher, L, Benedum, JL, Brandon, ML, Cutler, N, Ginsberg, D, Goswick, CB, Grubbs, AD, Kilpatrick, FW, Krusz, JC, Leonard, HA, Mondell, BE, Mumper, JD, Mushet, GR & So, E 1995, 'Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths', Neurology, vol. 45, no. 8, pp. S5-S9.
Cutler N, Mushet GR, Davis R, Clements B, Whitcher L, Benedum JL et al. Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths. Neurology. 1995;45(8):S5-S9.
Cutler, N. ; Mushet, G. R. ; Davis, R. ; Clements, B. ; Whitcher, L. ; Benedum, John L. ; Brandon, Milan L. ; Cutler, Neal ; Ginsberg, David ; Goswick, Claude B. ; Grubbs, Andrew D. ; Kilpatrick, Frank W. ; Krusz, John Claude ; Leonard, Hubert A. ; Mondell, Brain E. ; Mumper, James D. ; Mushet, George R. ; So, Elson. / Oral sumatriptan for the acute treatment of migraine : Evaluation of three dosage strengths. In: Neurology. 1995 ; Vol. 45, No. 8. pp. S5-S9.
@article{21a98cf0616241b0b8a6cb7ec8f5ee00,
title = "Oral sumatriptan for the acute treatment of migraine: Evaluation of three dosage strengths",
abstract = "This randomized, double–blind, parallel–group, placebo–controlled study evaluated the efficacy and tolerability of oral sumatriptan )Imitrex tablets( in 259 migraineurs. In the clinic, patients received oral sumatriptan 25 mg, 50 mg, or 100 mg, or placebo for the treatment of a migraine attack. The results indicate that by 2 hours post– dose, 50 to 56{\%} of patients treated with any of the three doses, compared with 26{\%} of patients treated with placebo, achieved relief of headache )p <; 0.05 for each sumatriptan group vs placebo(. By 4 hours postdose, 68 to 71{\%} of suma– triptan–treated patients, compared with 38{\%} of placebo–treated patients, achieved relief of headache )p < 0.05 for each sumatriptan group vs placebo(. Oral sumatriptan was similarly effective at relieving nausea and photophobia and at reducing clinical disability. The pattern and incidence of adverse events did not differ between treatment groups. All doses–25 mg, 50 mg, and 100 mg–of sumatriptan were effective and generally well tolerated. Dosing should be indi– vidualized according to the needs of the patient. NEUROLOGY 1995;45)suppl 7(:S5–S9",
author = "N. Cutler and Mushet, {G. R.} and R. Davis and B. Clements and L. Whitcher and Benedum, {John L.} and Brandon, {Milan L.} and Neal Cutler and David Ginsberg and Goswick, {Claude B.} and Grubbs, {Andrew D.} and Kilpatrick, {Frank W.} and Krusz, {John Claude} and Leonard, {Hubert A.} and Mondell, {Brain E.} and Mumper, {James D.} and Mushet, {George R.} and Elson So",
year = "1995",
language = "English (US)",
volume = "45",
pages = "S5--S9",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Oral sumatriptan for the acute treatment of migraine

T2 - Evaluation of three dosage strengths

AU - Cutler, N.

AU - Mushet, G. R.

AU - Davis, R.

AU - Clements, B.

AU - Whitcher, L.

AU - Benedum, John L.

AU - Brandon, Milan L.

AU - Cutler, Neal

AU - Ginsberg, David

AU - Goswick, Claude B.

AU - Grubbs, Andrew D.

AU - Kilpatrick, Frank W.

AU - Krusz, John Claude

AU - Leonard, Hubert A.

AU - Mondell, Brain E.

AU - Mumper, James D.

AU - Mushet, George R.

AU - So, Elson

PY - 1995

Y1 - 1995

N2 - This randomized, double–blind, parallel–group, placebo–controlled study evaluated the efficacy and tolerability of oral sumatriptan )Imitrex tablets( in 259 migraineurs. In the clinic, patients received oral sumatriptan 25 mg, 50 mg, or 100 mg, or placebo for the treatment of a migraine attack. The results indicate that by 2 hours post– dose, 50 to 56% of patients treated with any of the three doses, compared with 26% of patients treated with placebo, achieved relief of headache )p <; 0.05 for each sumatriptan group vs placebo(. By 4 hours postdose, 68 to 71% of suma– triptan–treated patients, compared with 38% of placebo–treated patients, achieved relief of headache )p < 0.05 for each sumatriptan group vs placebo(. Oral sumatriptan was similarly effective at relieving nausea and photophobia and at reducing clinical disability. The pattern and incidence of adverse events did not differ between treatment groups. All doses–25 mg, 50 mg, and 100 mg–of sumatriptan were effective and generally well tolerated. Dosing should be indi– vidualized according to the needs of the patient. NEUROLOGY 1995;45)suppl 7(:S5–S9

AB - This randomized, double–blind, parallel–group, placebo–controlled study evaluated the efficacy and tolerability of oral sumatriptan )Imitrex tablets( in 259 migraineurs. In the clinic, patients received oral sumatriptan 25 mg, 50 mg, or 100 mg, or placebo for the treatment of a migraine attack. The results indicate that by 2 hours post– dose, 50 to 56% of patients treated with any of the three doses, compared with 26% of patients treated with placebo, achieved relief of headache )p <; 0.05 for each sumatriptan group vs placebo(. By 4 hours postdose, 68 to 71% of suma– triptan–treated patients, compared with 38% of placebo–treated patients, achieved relief of headache )p < 0.05 for each sumatriptan group vs placebo(. Oral sumatriptan was similarly effective at relieving nausea and photophobia and at reducing clinical disability. The pattern and incidence of adverse events did not differ between treatment groups. All doses–25 mg, 50 mg, and 100 mg–of sumatriptan were effective and generally well tolerated. Dosing should be indi– vidualized according to the needs of the patient. NEUROLOGY 1995;45)suppl 7(:S5–S9

UR - http://www.scopus.com/inward/record.url?scp=0029351456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029351456&partnerID=8YFLogxK

M3 - Article

C2 - 7644082

AN - SCOPUS:0029351456

VL - 45

SP - S5-S9

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -